Skip to main content Skip to footer
Log in
Sign up

Curated Studies

Datasets from the following studies are currently curated on PKRxiv:

PKRxivStudy-0012: Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 72(3):289–296, 2016.

PKRxivStudy-0011: Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, Yuthavisuthi P, Neungton C, Huo Y, Smith E, Best BM, Mirochnick M. Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum. JAIDS Journal of Acquired Immune Deficiency Syndromes 59(3):245–252, 2012.

PKRxivStudy-0010: Eniayewu O, Azuka U, Ogah J, Adejuyigbe E, Bolaji O, Olagunju A. Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum. Clin Pharma and Therapeutics 116(4):1062–1070, 2024.

PKRxivStudy-0009: Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS 32(6):729–737, 2018.

PKRxivStudy-0008: Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs J-A, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med 16(9):e1002895, 2019.

PKRxivStudy-0007: Olagunju A, Bolaji O, Neary M, Back D, Khoo S, Owen A. Pregnancy affects nevirapine pharmacokinetics. Pharmacogenetics and Genomics 26(8):381–389, 2016.

PKRxivStudy-0006: Olagunju A, Khoo S, Owen A. Pharmacogenetics of Nevirapine Excretion into Breast Milk and Infants’ Exposure Through Breast Milk Versus Postexposure Prophylaxis. Pharmacogenomics 17(8):891–906, 2016.

PKRxivStudy-0004: Akinloye A, Eniayewu O, Adeagbo B, Bolaji O, Olagunju A. Validation and Clinical Application of a Liquid Chromatography–Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots. Therapeutic Drug Monitoring 44(3):430–437, 2022.

PKRxivStudy-0003: Akinloye A, Oyedeji T, Eniayewu O, Adeagbo B, Bolaji O, Rannard S, Owen A, Olagunju A. Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers. Future Pharmacology 4(1):163–172, 2024.

PKRxivStudy-0002: Olagunju A, Bolaji O, Amara A, Waitt C, Else L, Adejuyigbe E, Siccardi M, Back D, Khoo S, Owen A. Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants’ Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis 61(3):453–463, 2015.

PKRxivStudy-0001: Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, Oyigboja J, Back D, Khoo S, Owen A. Pharmacogenetics of pregnancy‐induced changes in efavirenz pharmacokinetics. Clin Pharma and Therapeutics 97(3):298–306, 2015.